Aura Biosciences, Inc.
AURAAura Biosciences is a clinical-stage biotechnology company developing a novel class of precision therapies called virus-like drug conjugates (VDCs) to treat solid tumors while preserving organ function.
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Aura Biosciences is a clinical-stage biotechnology company developing a novel class of precision therapies called virus-like drug conjugates (VDCs) to treat solid tumors while preserving organ function. The company's lead candidate, bel-sar, utilizes a dual mechanism of action that combines acute tumor cell necrosis via light activation with the stimulation of a long-term immune response. Aura is primarily focused on addressing high unmet needs in ocular oncology and urologic cancers, aiming to provide vision-sparing and organ-sparing alternatives to invasive standard-of-care treatments.
Aura is a pioneer in the VDC space, holding a leading position in the development of vision-sparing therapies for early choroidal melanoma with no currently approved drug competitors for that specific indication.
Questions, answered.
- What is Aura Biosciences, Inc.'s market cap?
- Aura Biosciences, Inc. (AURA) has a market capitalization of $740.6M and trades on NASDAQ.
- Who are Aura Biosciences, Inc.'s competitors?
- Aura Biosciences, Inc.'s key competitors include UroGen Pharma Ltd., ImmunityBio, Inc., Ideaya Biosciences, and others. These companies compete in similar markets and product categories.
- Who does Aura Biosciences, Inc. partner with?
- Aura Biosciences, Inc.'s notable partners include National Institutes of Health, Rakuten Medical, Inc., Clearside Biomedical, Inc., and others.
- Where is Aura Biosciences, Inc. headquartered?
- Aura Biosciences, Inc. is headquartered in United States of America and employs approximately 89 people. It has been publicly traded since 2021.